Review



human kidney carcinoma rhabdoid tumor cell line  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    ATCC human kidney carcinoma rhabdoid tumor cell line
    Human Kidney Carcinoma Rhabdoid Tumor Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 40 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human kidney carcinoma rhabdoid tumor cell line/product/ATCC
    Average 93 stars, based on 40 article reviews
    human kidney carcinoma rhabdoid tumor cell line - by Bioz Stars, 2026-05
    93/100 stars

    Images



    Similar Products

    human kidney carcinoma rhabdoid tumor cell line  (ATCC)
    93
    ATCC human kidney carcinoma rhabdoid tumor cell line
    Human Kidney Carcinoma Rhabdoid Tumor Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human kidney carcinoma rhabdoid tumor cell line/product/ATCC
    Average 93 stars, based on 1 article reviews
    human kidney carcinoma rhabdoid tumor cell line - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier
    atrt cell line chla02 atrt  (ATCC)
    93
    ATCC atrt cell line chla02 atrt
    Atrt Cell Line Chla02 Atrt, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/atrt cell line chla02 atrt/product/ATCC
    Average 93 stars, based on 1 article reviews
    atrt cell line chla02 atrt - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier
    research cell line source s chla02 atrt  (ATCC)
    93
    ATCC research cell line source s chla02 atrt
    Research Cell Line Source S Chla02 Atrt, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/research cell line source s chla02 atrt/product/ATCC
    Average 93 stars, based on 1 article reviews
    research cell line source s chla02 atrt - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier
    human atrt cell line chla 06  (ATCC)
    94
    ATCC human atrt cell line chla 06
    Human Atrt Cell Line Chla 06, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human atrt cell line chla 06/product/ATCC
    Average 94 stars, based on 1 article reviews
    human atrt cell line chla 06 - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier
    atrt cell lines  (ATCC)
    94
    ATCC atrt cell lines
    Activation markers of CD56 bright CD16 bright iPSC-NK cells. (A) The Immunocytochemistry data showed positive expression of the activation markers such as SH2D1A, NKG2D, CD107a, and inhibitory markers, KIR2DL and CD94 upon coculture with <t>(i)</t> <t>CHLA-02-ATRT</t> or (ii) CHLA-05-ATRT. (B) (i) The percentage expression of the activation markers, NKG2D and NKp46, in iPSC-NK cells before and after coculture was performed using flow cytometry. (ii) The relative gene expression of NK cell markers, including NKG2D, CD107a, NKp46, CD16a and CD56 after IL-15 treatment was also measured. KIR2DL1, killer cell immunoglobulin-like receptor 2DL1; SH2D1A, SH2 domain-containing protein 1A; NKG2D, NKG2-D type II integral membrane protein. The scale bar in (A) represents 100 μm, which corresponds to a 20x magnification. The statistically significant data are represented with “*”, “**”, and “***” for p- values <0.05, <0.01, and <0.001, respectively.
    Atrt Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/atrt cell lines/product/ATCC
    Average 94 stars, based on 1 article reviews
    atrt cell lines - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier
    viability assays atrt cell line chla 02 atrt  (ATCC)
    93
    ATCC viability assays atrt cell line chla 02 atrt
    Activation markers of CD56 bright CD16 bright iPSC-NK cells. (A) The Immunocytochemistry data showed positive expression of the activation markers such as SH2D1A, NKG2D, CD107a, and inhibitory markers, KIR2DL and CD94 upon coculture with <t>(i)</t> <t>CHLA-02-ATRT</t> or (ii) CHLA-05-ATRT. (B) (i) The percentage expression of the activation markers, NKG2D and NKp46, in iPSC-NK cells before and after coculture was performed using flow cytometry. (ii) The relative gene expression of NK cell markers, including NKG2D, CD107a, NKp46, CD16a and CD56 after IL-15 treatment was also measured. KIR2DL1, killer cell immunoglobulin-like receptor 2DL1; SH2D1A, SH2 domain-containing protein 1A; NKG2D, NKG2-D type II integral membrane protein. The scale bar in (A) represents 100 μm, which corresponds to a 20x magnification. The statistically significant data are represented with “*”, “**”, and “***” for p- values <0.05, <0.01, and <0.001, respectively.
    Viability Assays Atrt Cell Line Chla 02 Atrt, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/viability assays atrt cell line chla 02 atrt/product/ATCC
    Average 93 stars, based on 1 article reviews
    viability assays atrt cell line chla 02 atrt - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier
    atrt cell line chla 02 atrt  (ATCC)
    93
    ATCC atrt cell line chla 02 atrt
    Activation markers of CD56 bright CD16 bright iPSC-NK cells. (A) The Immunocytochemistry data showed positive expression of the activation markers such as SH2D1A, NKG2D, CD107a, and inhibitory markers, KIR2DL and CD94 upon coculture with <t>(i)</t> <t>CHLA-02-ATRT</t> or (ii) CHLA-05-ATRT. (B) (i) The percentage expression of the activation markers, NKG2D and NKp46, in iPSC-NK cells before and after coculture was performed using flow cytometry. (ii) The relative gene expression of NK cell markers, including NKG2D, CD107a, NKp46, CD16a and CD56 after IL-15 treatment was also measured. KIR2DL1, killer cell immunoglobulin-like receptor 2DL1; SH2D1A, SH2 domain-containing protein 1A; NKG2D, NKG2-D type II integral membrane protein. The scale bar in (A) represents 100 μm, which corresponds to a 20x magnification. The statistically significant data are represented with “*”, “**”, and “***” for p- values <0.05, <0.01, and <0.001, respectively.
    Atrt Cell Line Chla 02 Atrt, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/atrt cell line chla 02 atrt/product/ATCC
    Average 93 stars, based on 1 article reviews
    atrt cell line chla 02 atrt - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Activation markers of CD56 bright CD16 bright iPSC-NK cells. (A) The Immunocytochemistry data showed positive expression of the activation markers such as SH2D1A, NKG2D, CD107a, and inhibitory markers, KIR2DL and CD94 upon coculture with (i) CHLA-02-ATRT or (ii) CHLA-05-ATRT. (B) (i) The percentage expression of the activation markers, NKG2D and NKp46, in iPSC-NK cells before and after coculture was performed using flow cytometry. (ii) The relative gene expression of NK cell markers, including NKG2D, CD107a, NKp46, CD16a and CD56 after IL-15 treatment was also measured. KIR2DL1, killer cell immunoglobulin-like receptor 2DL1; SH2D1A, SH2 domain-containing protein 1A; NKG2D, NKG2-D type II integral membrane protein. The scale bar in (A) represents 100 μm, which corresponds to a 20x magnification. The statistically significant data are represented with “*”, “**”, and “***” for p- values <0.05, <0.01, and <0.001, respectively.

    Journal: Bioactive Materials

    Article Title: Feeder-free differentiation of human iPSCs into natural killer cells with cytotoxic potential against malignant brain rhabdoid tumor cells

    doi: 10.1016/j.bioactmat.2024.02.031

    Figure Lengend Snippet: Activation markers of CD56 bright CD16 bright iPSC-NK cells. (A) The Immunocytochemistry data showed positive expression of the activation markers such as SH2D1A, NKG2D, CD107a, and inhibitory markers, KIR2DL and CD94 upon coculture with (i) CHLA-02-ATRT or (ii) CHLA-05-ATRT. (B) (i) The percentage expression of the activation markers, NKG2D and NKp46, in iPSC-NK cells before and after coculture was performed using flow cytometry. (ii) The relative gene expression of NK cell markers, including NKG2D, CD107a, NKp46, CD16a and CD56 after IL-15 treatment was also measured. KIR2DL1, killer cell immunoglobulin-like receptor 2DL1; SH2D1A, SH2 domain-containing protein 1A; NKG2D, NKG2-D type II integral membrane protein. The scale bar in (A) represents 100 μm, which corresponds to a 20x magnification. The statistically significant data are represented with “*”, “**”, and “***” for p- values <0.05, <0.01, and <0.001, respectively.

    Article Snippet: In this study, two distinct types of ATRT cell lines, namely CHLA-05-ATRT (ATCC® CRL-3037TM, ATCC) and CHLA-02-ATRT (ATCC® CRL-3020TM, ATCC), were used to test the cytotoxic effect of iPSC-NK cells.

    Techniques: Activation Assay, Immunocytochemistry, Expressing, Flow Cytometry, Gene Expression, Membrane

    Degranulation marker expression and cytokine production in CD56 bright CD16 bright iPSC-NK cells after exposure to ATRT cells. (A) (i) Phase–contrast images showing coculture of iPSC-NK cells with CHLA-02-ATRT and CHLA-05-ATRT. (ii) Immunocytochemistry of degranulation marker CD107a in iPSC-NK cells after coculture with ATRT cells. (iii) Relative degranulation measurement in iPSC-NK cells before and after coculture with ATRT. “**”, p- value<0.01. (B) Cytokines production by human iPSC-NK cells. (i) Immunofluorescent images show positive TNF-alpha and IL-6 expression. (ii) iPSC-NK cells expressing IFN-gamma after exposure to CHLA-05-ATRT are quantified via flow cytometry. (iii) Cytokines released by iPSC-NK cells after exposure to interleukins, CHLA-05-ATRT, and CHLA-02-ATRT were quantified through ELISA assay. “*”, p -value<0.05. ns, non-significant difference. IL-6: Interleukin 6, TNF-a: Tumor necrosis factor alpha, IFN-gamma: Interferon-gamma. iNK:CD56 bright CD16 bright iPSC-derived NK cells, ILs: IL2, IL12, IL15, IL18, and IL21. Scale bar, 100 μm. The magnification is 20x for ICC images and 10x for phase-contrast images.

    Journal: Bioactive Materials

    Article Title: Feeder-free differentiation of human iPSCs into natural killer cells with cytotoxic potential against malignant brain rhabdoid tumor cells

    doi: 10.1016/j.bioactmat.2024.02.031

    Figure Lengend Snippet: Degranulation marker expression and cytokine production in CD56 bright CD16 bright iPSC-NK cells after exposure to ATRT cells. (A) (i) Phase–contrast images showing coculture of iPSC-NK cells with CHLA-02-ATRT and CHLA-05-ATRT. (ii) Immunocytochemistry of degranulation marker CD107a in iPSC-NK cells after coculture with ATRT cells. (iii) Relative degranulation measurement in iPSC-NK cells before and after coculture with ATRT. “**”, p- value<0.01. (B) Cytokines production by human iPSC-NK cells. (i) Immunofluorescent images show positive TNF-alpha and IL-6 expression. (ii) iPSC-NK cells expressing IFN-gamma after exposure to CHLA-05-ATRT are quantified via flow cytometry. (iii) Cytokines released by iPSC-NK cells after exposure to interleukins, CHLA-05-ATRT, and CHLA-02-ATRT were quantified through ELISA assay. “*”, p -value<0.05. ns, non-significant difference. IL-6: Interleukin 6, TNF-a: Tumor necrosis factor alpha, IFN-gamma: Interferon-gamma. iNK:CD56 bright CD16 bright iPSC-derived NK cells, ILs: IL2, IL12, IL15, IL18, and IL21. Scale bar, 100 μm. The magnification is 20x for ICC images and 10x for phase-contrast images.

    Article Snippet: In this study, two distinct types of ATRT cell lines, namely CHLA-05-ATRT (ATCC® CRL-3037TM, ATCC) and CHLA-02-ATRT (ATCC® CRL-3020TM, ATCC), were used to test the cytotoxic effect of iPSC-NK cells.

    Techniques: Marker, Expressing, Immunocytochemistry, Flow Cytometry, Enzyme-linked Immunosorbent Assay, Derivative Assay

    The cytotoxicity analysis of interleukins (ILs)-exposed iPSC-NK cells against ATRT cells. (A) Flow cytometry-based Calcein-AM assay. The quadrant plot displays the percentage expression of the live cell marker (Calcein-AM) on the x-axis and the dead cell marker (ETHD-1) on the y-axis for CHLA-02-ATRT or CHLA-05-ATRT after coculture with iPSC-NK cells. (B) The table depicts the percentage expression of live and dead cells as measured in (A). The live/dead ratio is observed to be lower in the coculture of both CHLA-02-ATRT and CHLA-05-ATRT with interleukin-exposed iPSC-NK cells compared to unexposed iPSC-NK cells. ILs: IL2, IL12, IL15, IL18, and IL21.

    Journal: Bioactive Materials

    Article Title: Feeder-free differentiation of human iPSCs into natural killer cells with cytotoxic potential against malignant brain rhabdoid tumor cells

    doi: 10.1016/j.bioactmat.2024.02.031

    Figure Lengend Snippet: The cytotoxicity analysis of interleukins (ILs)-exposed iPSC-NK cells against ATRT cells. (A) Flow cytometry-based Calcein-AM assay. The quadrant plot displays the percentage expression of the live cell marker (Calcein-AM) on the x-axis and the dead cell marker (ETHD-1) on the y-axis for CHLA-02-ATRT or CHLA-05-ATRT after coculture with iPSC-NK cells. (B) The table depicts the percentage expression of live and dead cells as measured in (A). The live/dead ratio is observed to be lower in the coculture of both CHLA-02-ATRT and CHLA-05-ATRT with interleukin-exposed iPSC-NK cells compared to unexposed iPSC-NK cells. ILs: IL2, IL12, IL15, IL18, and IL21.

    Article Snippet: In this study, two distinct types of ATRT cell lines, namely CHLA-05-ATRT (ATCC® CRL-3037TM, ATCC) and CHLA-02-ATRT (ATCC® CRL-3020TM, ATCC), were used to test the cytotoxic effect of iPSC-NK cells.

    Techniques: Flow Cytometry, Calcein AM Assay, Expressing, Marker

    Decrease in the viability of cancer cells upon exposure to CD56 bright CD16 bright iPSC-NK cells. (A) Ratio-dependent decrease in CHLA-02-ATRT and CHLA-05-ATRT cell viability upon coculture with CD56 bright CD16 bright iPSC-NK cells; (B) Ratio-dependent decrease in the viability of other types of tumor cells upon coculture with CD56 bright CD16 bright iPSC-NK cells, including SF8628, a diffuse intrinsic pontine glioma cell line, G401, a kidney rhabdoid tumor cell line, and A549, a lung carcinoma cell line. iNK, CD56 bright CD16 bright iPSC-NK. Statistical significance is denoted by *, **, and *** for p -values less than 0.05, 0.01, and 0.001, respectively.

    Journal: Bioactive Materials

    Article Title: Feeder-free differentiation of human iPSCs into natural killer cells with cytotoxic potential against malignant brain rhabdoid tumor cells

    doi: 10.1016/j.bioactmat.2024.02.031

    Figure Lengend Snippet: Decrease in the viability of cancer cells upon exposure to CD56 bright CD16 bright iPSC-NK cells. (A) Ratio-dependent decrease in CHLA-02-ATRT and CHLA-05-ATRT cell viability upon coculture with CD56 bright CD16 bright iPSC-NK cells; (B) Ratio-dependent decrease in the viability of other types of tumor cells upon coculture with CD56 bright CD16 bright iPSC-NK cells, including SF8628, a diffuse intrinsic pontine glioma cell line, G401, a kidney rhabdoid tumor cell line, and A549, a lung carcinoma cell line. iNK, CD56 bright CD16 bright iPSC-NK. Statistical significance is denoted by *, **, and *** for p -values less than 0.05, 0.01, and 0.001, respectively.

    Article Snippet: In this study, two distinct types of ATRT cell lines, namely CHLA-05-ATRT (ATCC® CRL-3037TM, ATCC) and CHLA-02-ATRT (ATCC® CRL-3020TM, ATCC), were used to test the cytotoxic effect of iPSC-NK cells.

    Techniques:

    Further maturation of iPSC-NK cells into CD56 -ve CD16 bright phenotype. (A) (i) Phase-contrast imaging on Day 65 and Day 70. (ii) Immunocytochemistry (ICC) images of CD56 and CD16. (iii) Flow cytometry quantification shows the highly positive expression of CD16 and low expression for the CD56 marker. (B) Immunocytochemistry detects the expression of CD56 and CD16 in iPSC-NK cells after activation using CHLA-02-ATRT, IL-15, and a combination of interleukins (IL2, IL12, IL15, IL18, and IL21). (C) The percentage expression of CD16 and CD56 under each condition remains relatively stable. Scale bar: 100 μm.

    Journal: Bioactive Materials

    Article Title: Feeder-free differentiation of human iPSCs into natural killer cells with cytotoxic potential against malignant brain rhabdoid tumor cells

    doi: 10.1016/j.bioactmat.2024.02.031

    Figure Lengend Snippet: Further maturation of iPSC-NK cells into CD56 -ve CD16 bright phenotype. (A) (i) Phase-contrast imaging on Day 65 and Day 70. (ii) Immunocytochemistry (ICC) images of CD56 and CD16. (iii) Flow cytometry quantification shows the highly positive expression of CD16 and low expression for the CD56 marker. (B) Immunocytochemistry detects the expression of CD56 and CD16 in iPSC-NK cells after activation using CHLA-02-ATRT, IL-15, and a combination of interleukins (IL2, IL12, IL15, IL18, and IL21). (C) The percentage expression of CD16 and CD56 under each condition remains relatively stable. Scale bar: 100 μm.

    Article Snippet: In this study, two distinct types of ATRT cell lines, namely CHLA-05-ATRT (ATCC® CRL-3037TM, ATCC) and CHLA-02-ATRT (ATCC® CRL-3020TM, ATCC), were used to test the cytotoxic effect of iPSC-NK cells.

    Techniques: Imaging, Immunocytochemistry, Flow Cytometry, Expressing, Marker, Activation Assay

    Characterization of the activation markers in CD56 -ve CD16 bright iPSC-NK cells and their cytotoxicity toward ATRT cells. (A–B) Immunocytochemistry and flow cytometry data indicate the absence of expression for NKG2D and NKp46 markers. At this stage, NKG2D in iPSC-NK cells was not upregulated after coculture with CHLA-02-ATRT. (C) Effects of ILs-exposed iPSC-NK cells versus ILs-unexposed iPSC-NK cells on cell viability of CHLA-02-ATRT and CHLA-05-ATRT cells have no statistically significant decrease in cell viability compared to the untreated group, E: T = 0:1. ns, non-significant difference. The data were verified by two independent experiments, and each experiment has triplicates (n = 3).

    Journal: Bioactive Materials

    Article Title: Feeder-free differentiation of human iPSCs into natural killer cells with cytotoxic potential against malignant brain rhabdoid tumor cells

    doi: 10.1016/j.bioactmat.2024.02.031

    Figure Lengend Snippet: Characterization of the activation markers in CD56 -ve CD16 bright iPSC-NK cells and their cytotoxicity toward ATRT cells. (A–B) Immunocytochemistry and flow cytometry data indicate the absence of expression for NKG2D and NKp46 markers. At this stage, NKG2D in iPSC-NK cells was not upregulated after coculture with CHLA-02-ATRT. (C) Effects of ILs-exposed iPSC-NK cells versus ILs-unexposed iPSC-NK cells on cell viability of CHLA-02-ATRT and CHLA-05-ATRT cells have no statistically significant decrease in cell viability compared to the untreated group, E: T = 0:1. ns, non-significant difference. The data were verified by two independent experiments, and each experiment has triplicates (n = 3).

    Article Snippet: In this study, two distinct types of ATRT cell lines, namely CHLA-05-ATRT (ATCC® CRL-3037TM, ATCC) and CHLA-02-ATRT (ATCC® CRL-3020TM, ATCC), were used to test the cytotoxic effect of iPSC-NK cells.

    Techniques: Activation Assay, Immunocytochemistry, Flow Cytometry, Expressing